Inhibition of retinal neovascularization by siRNA targeting VEGF$_{165}$

Xiao-bo Xia, Si-qi Xiong, Wei-tao Song, Jie Luo, Yu-ke Wang, Rong-rong Zhou

Department of Ophthalmology, Xiangya Hospital, Central South University, Changsha, China

**Purpose:** To investigate whether vector-based vascular endothelial growth factor 165 (VEGF)$_{165}$ targeted siRNA expression system (pSilencer$_{siVEGF}$) could inhibit VEGF$_{165}$ expression in vitro and suppress retinal neovascularization in the murine model of oxygen-induced retinopathy.

**Methods:** pSilencer$_{siVEGF}$, from which siRNA targeting VEGF$_{165}$ could be generated, was constructed and transfected to human umbilical vein endothelial cells. Then the level of VEGF isoforms in cultured cells was measured by RT–PCR and ELISA. Intravitreal injection of pSilencer$_{siVEGF}$ was performed in mice with ischemic retinopathy. Retinal neovascularization was evaluated by angiography using fluorescein-labeled dextran and quantitated histologically. The levels of VEGF$_{164}$, which is equivalent to human VEGF$_{165}$ in murine retinas were determined by RT–PCR and western immunoblotting.

**Results:** Expression of VEGF$_{165}$ in cultured cells was greatly curtailed by pSilencer$_{siVEGF}$ under both normoxia and hypoxia conditions. However, the other isoforms, VEGF$_{164}$ and VEGF$_{121}$, were expressed to a similar degree regardless of whether pSilencer$_{siVEGF}$ was administered. Based on angiography and histological analysis, retinal neovascularization in the eyes treated with pSilencer$_{siVEGF}$ were significantly reduced compared to the control eyes. Furthermore, the VEGF$_{164}$ levels in the murine retinas were suppressed by pSilencer$_{siVEGF}$.

**Conclusions:** Retinal neovascularization in the murine model was significantly attenuated by pSilencer$_{siVEGF}$ through decreasing VEGF$_{164}$ levels in the retinas. pSilencer$_{siVEGF}$ seems to be a potential therapeutic tool for ischemic-induced retinal diseases.

Retinal neovascularization, abnormal formation of new vessels from preexisting capillaries in the retina, is a common complication of many ocular diseases, such as advanced diabetic retinopathy, and retinopathy of prematurity. Neovascularization can lead to fibrosis and disruption of delicate tissues required for vision. Laser photocoagulation as conventional treatment is effective in halting the progression of angiogenesis in the short-term. However, it is also destructive to the retinal tissue, leads to immediate and sometimes significant loss of vision, and does not address the underlying angiogenic mechanisms of the disease. Therefore, therapy targeting molecular mechanisms underlying retinal neovascularization may provide better treatment result and fewer detrimental side effect.

Angiogenesis is a complex process, involving multiple gene products expressed by different cell types, all contributing to an integrated sequence of events. However, laboratory studies have demonstrated that vascular endothelial growth factor (VEGF) plays a central role in several retinal vascular diseases. Clinical trials have confirmed the importance of VEGF in disease pathogenesis [1,2]. Consequently, VEGF becomes an optimal target for inhibition of retinal neovascularization. Accumulated data indicate that attenuation of VEGF activity could effectively suppress retinal neovascularization. Recent treatments based on antibody technology have been proven to be efficacious. Lucentis, a anti-VEGF antibody fragment, has been approved as an antiangiogenic drug for the treatment of ocular neovascularization [3]. Although antibodies are effective, they are not efficient. Large amounts of antibodies are needed to suppress the targeted protein, and the inhibitory effects of antibodies are transient unless these high doses are administered repeatedly.

RNA interference (RNAi) is a recently developed technique to silence proteins in a sequence-specific manner by inhibiting mRNA and consequently reducing protein expression. The high efficiency and specificity of RNAi has made it a powerful and widely used tool for gene therapy. The functional mediator of RNAi is a short double strand RNA (dsRNA) oligonucleotide called small interfering RNA (siRNA) [4]. A growing number of investigations are examining the use of siRNA as a candidate therapeutic agent. Currently, there are two siRNA-based molecules: Cand5, which is a siRNA against all isoforms of VEGF, and siRNA-027, a kind of siRNA targeting VEGF receptor 1 [5]. Acuity Pharmaceuticals (Philadelphia, PA) has begun a Phase II clinical trial for Cand5, and Sirna Therapeutics (San Francisco, CA) is on a Phase 1 clinical trial for siRNA-027. However, due to differential pre-mRNA splicing, a single
VEGF gene gives rise to many different VEGF isoforms. To date, five isoforms of human VEGF have been identified: VEGF₁₂₁, VEGF₁₄₅, VEGF₁₆₅, VEGF₁₈₉, and VEGF₂₅₆ [6]. Although VEGF is highly conserved throughout evolution, the murine homologs contain one fewer amino acid. The murine designation for the human VEGF₁₆₅ is VEGF₁₆₄. Of the various isoforms, VEGF₁₆₅ (VEGF₁₄₅) appears to be the major pathological VEGF isoform in the eye [7]. Because VEGF₁₆₅ is a major disease-causing isofrom in models of neovascular eye disease, we expected to identify whether retinal angiogenesis could be attenuated by siRNA targeting VEGF₁₆₅.

In this report, we used a vector-based siRNA expression system, which overcomes the limitations of transience and high cost in synthetic siRNAs, to specifically inhibit VEGF₁₆₅ expression in the murine model of proliferative retinopathy. Our data confirm the potential VEGF₁₆₅ inhibitors for the treatment of ocular angiogenesis.

METHODS

Recombinant pSilencer-siVEGF construction: The cDNA oligonucleotides targeting VEGF₁₆₅ mRNA were designed and examined by Guan et al. [13]. A pair of 63 nucleotide oligos containing endonuclease restriction sites at both ends was synthesized by the Sangong Company (Shanghai, China). The sequences used were: First strand-5′–GAT CCG ATA GAG CAA GAC AAG AAA TTC AAG AGA TTT GTC TTG TTG TGG AAA–3′; Second strand-5′–AGC TTT TCC AAA AAA GAT AGA GCA AGA CAA GAA ATC TTT GAA TTT CTT GTC TTG GTC TAT CG–3′ (complementary sequence is indicated in red). The annealed dsDNA oligonucleotides were ligated between the BamHI and HindIII sites on the pSilencer2.1-U6 hygro vector. The targeted VEGF₁₆₅ sequences were GAT AGA GCA AGA C 3′ (sense) and 5′-TCC TGG TGA G-3′ (antisense), was used to amplify human VEGF isoforms in cultured cells. The primer pair, 5′-AGC TTT TCC AAA AAA GAT AGA GCA AGA CAA GAA ATC TTT GAA TTT CTT GTC TTG GTC TAT CG–3′ (antisense), was designed to yield the PCR products of murine VEGF isoforms. The primer pair, 5′-TCC CCG AAA CCA TGA ACT TTC TGG TC-3′ (sense) and 5′-CAG CCT GGC TCA CCG CCT TGG CTT-3′ (antisense), was used to obtain the PCR product of β-actin.

Reverse transcription and polymerase chain reaction: Whole RNA of cultured cells or murine retinas were isolated using TRIzol® reagent (Invitrogen). Total RNA was isolated using Trizol reagents (Gibco-BRL Life Technologies, Gibco, Carlsbad, CA), followed by treatment for 45 min with RNase-free DNase at 37 °C (Message Clean; GeneHunter Corp., Nashville, TN), phenol:chloroform (ratio 1:1) extraction, ethanol precipitation, and stabilizing in DEPC-treated water. RNA concentration was determined by spectrophotometric readings at 260 and 280 nm. Each 2 µg of RNA extract was reverse-transcribed into cDNA with RevertAidTM First Strand cDNA Synthesis Kit (MBI, Burlington, MD). PCR was performed in 50 µl of a solution containing Taq DNA polymerase, dNTP, VEGF primer, or β-actin primer and RT products. The primer pair, 5′-CGA AGT GGT GAA GAT CAT GGA TG-3′ (sense) and 5′-TTG TG A GAC AGT CAG AGA TG GA-3′ (antisense), was used to humify human VEGF isoforms in cultured cells.

The primer pair, 5′-AGA CAA GCA AGA C 3′ (sense) and 5′-TGC AAG GAT GAC AGT CAG AGA TG-3′ (antisense), was used to amplify human VEGF isoforms in cultured cells. The primer pair, 5′-CGA AGT GGT GAA GAT CAT GGA TG-3′ (sense) and 5′-TTG TG A GAC AGT CAG AGA TG GA-3′ (antisense), was used to humify human VEGF isoforms in cultured cells.

ELISA assay for VEGF production: The medium from normoxia and hypoxia cultured cells was collected, centrifuged at 750×g for 5 min, and stored at −70 °C. Concurrently, cells were trypsinized and counted. The concentration of the secreted VEGF₁₆₅ isoform in the serum was determined with an ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions and was expressed as pg VEGF/10⁵ cells.

Animal model of proliferative retinopathy: The study protocol conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The reproducible murine model of oxygen-induced retinopathy (OIR) has been described previously [8]. C57BL/6J mice were bought from Experimental Animal Center of Central South University, Changsha, Hunan province, China. The mice were exposed to less than 300 lx of 12 h cyclical broad spectrum light. The oxygen-treated mice were housed in an incubator. Oxygen concentration was monitored with a Beckman oxygen analyzer (Model D2; Beckman, Irvine, CA). The cage
liposome-pSilencer complexes were performed at P12 as described in the next section. At P17, the mice were sacrificed by cardiac perfusion of 4% paraformaldehyde in phosphate-buffered saline (PBS) catalog number of PBS is 20012043 (Gibco), and their eyes were enucleated for RT–PCR and immunohistologic analysis. Alternatively, some mice underwent retinal fluorescein angiography, as described in the next section.

**Intravitreal injections:** At P12, mouse pupils were deeply anesthetized with a 30 mg/kg intraperitoneal injection of sodium pentobarbital. The lid fissure was opened with a no. 11 scalpel blade, and the eye was proptosed. Intravitreal injections were performed by first entering the eye with an Ethicon TG140–8 suture needle at the posterior limbus. A 32-gauge Hamilton needle and syringe were used to deliver 1 µl pSilencer siVEGF complexes were performed at P12 as described in the next section. At P17, the mice were sacrificed by cardiac perfusion of 4% paraformaldehyde in phosphate-buffered saline (PBS) catalog number of PBS is 20012043 (Gibco), and their eyes were enucleated for RT–PCR and immunohistologic analysis. Alternatively, some mice underwent retinal fluorescein angiography, as described in the next section.

**Intravitreal injections:** At P12, mouse pupils were deeply anesthetized with a 30 mg/kg intraperitoneal injection of sodium pentobarbital. The lid fissure was opened with a no. 11 scalpel blade, and the eye was proptosed. Intravitreal injections were performed by first entering the eye with an Ethicon TG140–8 suture needle at the posterior limbus. A 32-gauge Hamilton needle and syringe were used to deliver 1 µl liposome-pSilencer siVEGF complex (0.5 µl liposome and 1–1000 ng of pSilencer siVEGF) or 1 µl control complex (0.5 µl liposome and 0.5 µl of 2 mg/ml pSilencer null vector) into the vitreous cavity.

**Angiography with high-molecular-weight fluorescein-dextran:** At P17, mice were anesthetized with a 30 mg/kg intraperitoneal injection of sodium pentobarbital. The lid fissure was opened with a no. 11 scalpel blade, and the eye was proptosed. Intravitreal injections were performed by first entering the eye with an Ethicon TG140–8 suture needle at the posterior limbus. A 32-gauge Hamilton needle and syringe were used to deliver 1 µl liposome-pSilencer siVEGF complex (0.5 µl liposome and 1–1000 ng of pSilencer siVEGF) or 1 µl control complex (0.5 µl liposome and 0.5 µl of 2 mg/ml pSilencer null vector) into the vitreous cavity.

**Histological analysis of neovascularization:** The eyes of sacrificed P17 mice were enucleated, fixed overnight with 4% paraformaldehyde in PBS, and embedded in paraffin. Half of the group of mice were used for angiography with high-molecular-weight fluorescein-dextran, and the other half were used for histological analysis of neovascularization. Paraffin-embedded axial serial sections of the retina, 6 µm thick, were obtained starting at the optic nerve head. After staining with periodic acid-Schiff reagent and hematoxylin, we evaluated 10 intact sections of equal length, each 30 µm apart, for a span of 300 µm. All retinal vascular cell nuclei anterior to the internal limiting membrane were counted in each section according to a masked protocol. The mean of all ten counted sections yielded average neovascular cell nuclei per 6 µm section per eye.

**Western blot analysis of VEGF in the murine retina:** The murine retinas were collected and lysed in lysis buffer composed of 150 mmol/l NaCl, 50 mmol/l Tris-HCl, pH 7.4, 2 mmol/l EDTA, and 1% NP-40 that also contained protease inhibitors (Boehringer Mannheim, Mannheim, Germany). Total protein (30 µg per lane) was loaded on SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane and incubated with a 1:500 dilution rat monoclonal anti-VEGF antibody Santa Cruz (Santa Cruz, CA, catalog number sc-80436) and a 1:10,000 dilution mouse monoclonal anti-β-actin antibody (Sigma, St. Louis, MO), followed by incubation with corresponding secondary antibodies (peroxidase conjugated). The enhanced chemiluminescence (ECL) chemiluminescence reagent was added to the membrane according to the manufacturer’s directions. The membrane was exposed to an X-ray film for 1 min before it was developed and fixed. Images of blots were entered into a computer using a scanner (Epson, Nagano, Japan) and analyzed using LabWorks Software (UVP). Then, values were transferred to an Excel spreadsheet for calculation of means and standard errors.

**Statistics:** The results were expressed as mean±standard error of mean (SEM). One-way ANOVA followed by the least significant difference (LSD)-t-test were used to evaluate significant differences. A p value <0.05 was considered statistically significant.

**RESULTS**

**Suppression of VEGF<sub>165</sub> expression in cultured cells by pSilencer<sup>siVEGF</sup>:** To determine whether vector-based VEGF<sub>165</sub> targeted siRNA expression system (pSilencer<sup>siVEGF</sup>) could suppress the expression of VEGF<sub>165</sub>, we transfected pSilencer<sup>siVEGF</sup> plasmid to HUVECs. Then the transfected cells were further cultured under normoxia (20% O<sub>2</sub>) and hypoxia (1% O<sub>2</sub>) conditions for 24 h, together with null vector transfected and non-transfected HUVECs (as control). All these cells were later used for RT–PCR and ELISA analysis. As shown in Figure 1A,B, VEGF<sub>165</sub> mRNA levels in pSilencer<sup>siVEGF</sup> transfected cells were dramatically decreased under both normoxic and hypoxic conditions compared to the control cells (p<0.05), while VEGF<sub>121</sub> and VEGF<sub>189</sub> were expressed to a similar degree regardless of whether pSilencer<sup>siVEGF</sup> was applied. Correspondingly, the amount of VEGF<sub>165</sub> protein secreted into the medium of cultured cells was greatly inhibited after pSilencer<sup>siVEGF</sup> transfection (Figure 1C), indicating that pSilencer<sup>siVEGF</sup> could specifically decrease VEGF<sub>165</sub> expression in cultured cells without alteration of other VEGF isoforms expression under both normoxia and hypoxia conditions.

**Angiographic evaluation of the effect of pSilencer<sup>siVEGF</sup> on retinal neovascularization:** Injection of liposome–pSilencer<sup>siVEGF</sup> complexes was performed at P12. Injection of fluorescein-labeled dextran into left ventricle was done at P17, followed by retina flatmount. The retinas of room air-raised mice revealed a normal capillary network without nonperfusion area and neovascular tufts. However, retinas...
from hyperoxia-exposed mice with pSilencer null vector injection or without any injection contained multiple neovascular tufts and central nonperfusion areas. In contrast, fewer neovascular complexes could be found in retinas of mouse eyes injected with pSilencer

siVEGF (Figure 2).

**Histological analysis of retinal neovascularization:** Neovascularization was assessed histologically by counting the endothelial cell nuclei anterior to the inner limiting membrane. Retinas from hyperoxia-exposed mice with injection of 1000 ng pSilencer null vector or without any injection (OIR model) were found to contain multiple neovascular tufts extending into the vitreous. In contrast, fewer neovascular complexes were observed in pSilencer

siVEGF-injected retinas (Figure 3). Administration of 1–1000 ng doses of pSilencer

siVEGF resulted in a dose-dependent decrease in endothelial cell nuclei numbers anterior to the inner limiting membrane (i.e., inhibition of retinal neovascularization), with a maximum inhibitory effect of 50% at the 1000 ng dose (Figure 4).

**Inhibition of VEGF<sub>164</sub> expression in murine retinas by pSilencer<sup>siVEGF</sup>:** To determine whether intravitreal injection of pSilencer

siVEGF could decrease VEGF<sub>164</sub> expression in the murine retinas, we extracted retinas and assessed them by RT–PCR and immunohistochemical analysis. Some retinas were used for RNA extraction and RT–PCR analysis, the others were embedded in paraffin and examined by immunohistochemistry. Figure 5A,B show the PCR products of VEGF isoforms in the murine retinas. Compared to the control eyes, the level of VEGF<sub>164</sub> mRNA was significantly downregulated in the retinas of hypoxic animals treated with pSilencer

siVEGF, whereas VEGF<sub>121</sub> and VEGF<sub>189</sub> levels in the murine retinas remained unchanged after local administration of pSilencer

siVEGF. To confirm the effect of pSilencer<sup>siVEGF</sup> on the expression level of VEGF<sub>164</sub> at the protein level, we performed immunohistochemical studies to investigate VEGF<sub>164</sub> expression patterns in the retinas of the murine model of OIR. We performed western immunoblotting to assess the VEGF164 protein level in the retinas of the murine model of OIR. As shown in Figure 5C,D, local administration of pSilencer<sup>siVEGF</sup> significantly decreased expression of VEGF protein in the murine retinas.

**DISCUSSION**

Vascular homeostasis is regulated by two counter-balancing systems: angiogenic stimulators and angiogenic inhibitors [9,10]. Under pathological conditions, such as diabetic...
retinopathy and retinopathy of prematurity, the retina increases the production of angiogenic stimulators and reduces the production of angiogenic inhibitors, which would disrupt the balance between the positive and negative regulators of angiogenesis [9]. VEGF as major angiogenic stimulator is upregulated in ocular neovascular diseases [11]. However, due to alternative splicing of mRNA, VEGF has multiple isoforms. VEGF_{165} (VEGF_{164} in mice) is the major disease-causing isoform in models of neovascular eye disease. VEGF_{165} was found to be more potent than other VEGF isoforms in inducing vascular leakage and breakdown of blood-retinal barrier [12]. Hence, VEGF_{165} was selected for this study as a target for suppressing retinal neovascularization. We hoped that therapy targeting VEGF_{165} in the retina could increase specificity and efficacy of the treatment.

To decrease pathological VEGF_{165} upregulation, we constructed a vector-based VEGF_{165} targeted siRNA expression system (pSilencer^{siVEGF}) for our studies. pSilencer^{siVEGF} has been shown to specifically inhibit VEGF_{165} expression in normoxia-cultured tumor cells [13]. It has been hypothesized that sustained overproduction of

Figure 2. Angiographic analysis of the effect of pSilencer^{siVEGF} on the murine model of retinal neovascularization. Retinal flatmounts were examined by fluorescein dextran angiography. A: Shown is a retinal flatmount of mice raised in room air. B: In this retinal flatmount of mice exposed to hyperoxia, neovascular tufts appear as hyperfluorescence at the junction between the perfused and the nonperfused area. Arrow points to retinal neovascularization, and star marks an area of nonperfusion. C: In this retinal flatmount of hyperoxia exposed mice injected with pSilencer null vector, retinal neovascularization and nonperfusion area were not attenuated. D: Shown is a retinal flatmount of hyperoxia-exposed mice injected with pSilencer^{siVEGF}. The amount of neovascular tufts was markedly reduced and the area of nonperfusion was diminished.
VEGF by hypoxia retinal cells promotes retinal neovascularization in several neovascular eye diseases [1]. Consequently, close attention was paid to whether pSilencer<sup>siVEGF</sup> could work properly under hypoxia conditions. VEGF was found to be decreased dramatically not only in the hypoxia cultured cells but also in the hypoxia retinal cells in the murine animal models, suggesting that hypoxia-induced VEGF could be abrogated by pSilencer<sup>siVEGF</sup> under hypoxia conditions. We surmise that overproduction of VEGF by hypoxia retinal cells may also be blocked by pSilencer<sup>siVEGF</sup> in human neovascular eye diseases such as diabetic retinopathy.

Figure 3. Histological analysis of the effects of treatment with pSilencer<sup>siVEGF</sup> on ischemia-induced retinal neovascularization. A: Postnatal day 17 (P17) retina from the eye of a hypoxic mouse injected with 1000 ng pSilencer null vector. Extensive preretinal neovascular loops are apparent (black arrows). B: P17 retina from the eye of hypoxic mouse injected with 1000 ng pSilencer<sup>siVEGF</sup>. Preretal neovascular loops were not as apparent, suggesting that treatment reduced preretinal neovascularization compared with the pSilencer null vector-injected eye. The following abbreviations were used in the figure: interlimiting membrane (ILM), ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL).

Figure 4. Dose-dependent inhibition of retinal neovascularization by pSilencer<sup>siVEGF</sup>. Administration of pSilencer<sup>siVEGF</sup> at doses 1–1000 ng to hypoxic mice resulted in a dose-dependent inhibition of retinal neovascularization as measured by counting the number of endothelial cell nuclei per section, with a maximum inhibitory effect of 50% at the 1000 ng dose. Asterisk (*) indicates p<0.05 compared to the control eye.
Figure 5. Suppression of vascular endothelial growth factor expression in murine retinas by pSilencer<sup>siVEGF</sup>. Murine retinas were extracted and examined for VEGF level. One-way ANOVA followed by the LSD-t-test were used to evaluate significant differences. A p value <0.05 was considered statistically significant. Error bars are standard error of mean (SEM).

**A:** VEGF<sub>120</sub>, VEGF<sub>164</sub>, and VEGF<sub>188</sub> mRNA levels in murine retinas were examined by RT–PCR. VEGF<sub>164</sub> mRNA in murine retinas was downregulated after intravitreal administration of pSilencer<sup>siVEGF</sup>, whereas VEGF<sub>120</sub> and VEGF<sub>188</sub> levels in murine retinas remained unchanged. Lanes are marked as follows: 1) room air-raised mice; 2) murine model with pSilencer<sup>siVEGF</sup> injection; 3) murine model with pSilencer null vector injection; and 4) murine model of oxygen-induced retinopathy.

**B:** Relative VEGF isoforms mRNA quantification was related to β-actin mRNA.

**C:** Shown is an immunoblot assay for VEGF<sub>165</sub> protein in the murine retinas. The total amount of VEGF<sub>164</sub> immunosignal in murine retinas was reduced by pSilencer<sup>siVEGF</sup>. The following abbreviations are used in panel C: ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL).

**D:** The levels of VEGF<sub>165</sub> were quantitated by densitometry and normalized to β-actin protein levels. Data are expressed as mean±SEM and were analyzed by one-way ANOVA followed by LSD-t-test. The means of groups 3 and 4 are statistically greater than the means of groups 1 and 2 (p<0.05).
In the current study, retinal neovascularization in the murine model was greatly inhibited by 1000 ng of pSilencer<sub>165</sub>VEGF. This dramatic decrease in retinal neovascularization could be attributed to the following reasons. First, the localization of plasmids mediated by cationic liposome is close to the site of hypoxia-induced VEGF generation. VEGF<sub>164</sub> level in the retinas of the murine model was found to increase in the inner nuclear layer and ganglion cell layer in this study, which was consistent with a previous study [14]. However, cationic liposome has been confirmed as an effective reagent for retinal gene transfer, which could carry plasmids into retinal ganglion cells and retinal pigment epithelial cells through the injection of plasmids and liposome complex into the vitreous [15]. Accordingly, intravitreal injections of pSilencer<sub>165</sub>VEGF could be successfully carried into retinal cells, which are in charge of producing hypoxia-induced VEGF by liposome. Second, the catalytic nature of RNAi entered the retinal cells. Small hairpin RNA (shRNA) targeting VEGF<sub>165</sub> could be generated and processed into siRNA in these cells. The siRNA targeting VEGF<sub>165</sub> binds to the RNA induced silencing complex (RISC), which in turn becomes activated. The activated RISC complex seeks out the VEGF<sub>165</sub> mRNA and then splices the mRNA at the site of the homologous sequence [4]. Furthermore, in multiple turnover kinetic fashion, the activated RISC can seek another VEGF<sub>165</sub> mRNA to bind and destroy. One activated RISC complex can bind and destroy hundreds of VEGF<sub>165</sub> mRNA. Finally, the high efficiency of pSilencer<sub>165</sub>VEGF is attributed to the divisional rate of the retinal cells. The division rate of cells that have taken in siRNA is an important factor when determining durability of silencing in cells [16], which leads to dilution of the activated RISC as it is divided between daughter cells. Because the division rate of retinal cells is slow, the silencing effect in the cells could last until upregulation of VEGF in ischemic retina disappears.

In summary, we found that siRNA targeting VEGF<sub>165</sub> expressed from pSilencer<sub>165</sub>VEGF could decrease VEGF<sub>165</sub> expression in vitro and reduce retinal neovascularization in a murine model of OIR. However, further experiments are necessary to determine whether detrimental side effects will appear after local administration of pSilencer<sub>165</sub>VEGF.

ACKNOWLEDGMENTS
This research was supported by National Natural Science Foundation of China.

REFERENCES
1. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72:638-45. [PMID: 7540233]
2. Joško J, Gwóźdź B, Jedrzejowska-Szyプulka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 6:1047-52. [PMID: 11208453]
3. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. MARINA Study GroupSubgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114:246-52. [PMID: 17270674]
4. Elbashir SM, Lendeckel W, Tuschi T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200. [PMID: 11157775]
5. Check E. Firm sets sights on gene silencing to protect vision. Nature 2004; 430:819. [PMID: 15318183]
6. Zachary I. Vascular endothelial growth factor. Int J Biochem Cell Biol 1998; 30:1169-74. [PMID: 9839443]
7. Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adams AP. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198:483-9. [PMID: 12900522]
8. Smith LE, Wosolowsky E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35:101-11. [PMID: 7507904]
9. Miller JW, Adams AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13:37-50. [PMID: 9134347]
10. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997; 22:251-6. [PMID: 9255066]
11. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285:245-8. [PMID: 10398599]
12. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res 2006; 312:527-37. [PMID: 16300026]
13. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing’s Sarcoma Growth in a Xenograft Mouse Model. Clin Cancer Res 2005; 11:2662-9. [PMID: 15814647]
14. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA. Hypoxia inducible factor-1 alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999; 40:182-9. [PMID: 9888442]
15. Masuda I, Matsuo T, Yasuda T, Matsuo N. Gene transfer with intraocular tissues by different routes of administration. Invest Ophthalmol Vis Sci 1996; 37:1914-20. [PMID: 8759362]
16. Dykshoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003; 4:457-67. [PMID: 12778125]
